Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China
WATERTOWN, Mass. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has entered into an
View HTML
Toggle Summary Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
̶   Eravacycline Did Not Achieve Co-Primary Endpoints in cUTI Trial   ̶ ̶   Company Continues to Prepare for Commercialization of Eravacycline as a Treatment for cIAI in the U.S. and Europe , Assuming Regulatory Approval    ̶ ̶   Conference Call Scheduled for Today at 4:30 p.m.
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the promotion of Larry Tsai , M.D., Vice
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
Submission Supported by Positive Data from IGNITE1 and IGNITE4 Clinical Trials WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant
View HTML
Toggle Summary Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
WATERTOWN, Mass. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has been selected for addition to the
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017
WATERTOWN, Mass. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will participate in a
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements
WATERTOWN, Mass. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
WATERTOWN, Mass. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the appointment of Kamalam (Kam) Unninayar as
View HTML
Toggle Summary Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017
- Company plans to advance current oral eravacycline formulation into a phase 2 study in 1H18 -
View HTML